Page last updated: 2024-09-03

r-1-(6-(r-2-carboxypyrrolidin-1-yl)-6-oxohexanoyl)pyrrolidine-2-carboxylic acid and Amyloidosis

r-1-(6-(r-2-carboxypyrrolidin-1-yl)-6-oxohexanoyl)pyrrolidine-2-carboxylic acid has been researched along with Amyloidosis in 11 studies

Research

Studies (11)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (36.36)29.6817
2010's5 (45.45)24.3611
2020's2 (18.18)2.80

Authors

AuthorsStudies
Al Azzam, W; Antoni, G; Bergström, M; Biswas, S; Chen, C; Cheriyan, J; Cleveland, M; Cookson, L; Falk, RH; Galette, P; Janiczek, RL; Kwong, RY; Lukas, MA; Millns, H; Richards, D; Schneider, I; Solomon, SD; Sörensen, J; Storey, J; Thompson, D; van Dongen, G; Vugts, DJ; Wall, A; Wechalekar, A; Wikström, G1
Cookson, L; Lukas, MA; Millns, H; Richards, D1
Pepys, MB; Pepys-Vered, ME1
Barton, SV; Berges, AC; Cookson, LM; Fontana, M; Gillmore, JD; Hawkins, PN; Lane, T; Moon, JC; Pepys, MB; Pinzani, M; Richards, DB; Ritter, JM1
Kolstoe, SE; Wood, SP1
Hutchinson, WL; Millar, DJ; Pepys, MB1
Gironella-Mesa, M; Martínez-Valle, F; Solans-Laqué, R1
Eikelenboom, P; Lemstra, AW; Meijer, EW; van Gool, WA1
Hirschfield, GM1
Gillmore, JD; Hawkins, PN1
Alanine, A; Bartfai, T; Gallimore, JR; Hawkins, PN; Herbert, J; Hertel, C; Hoffmann, T; Hutchinson, WL; Jakob-Roetne, R; Kemp, JA; Kolstoe, S; Lachmann, HJ; Lovat, LB; Murray, S; Norcross, RD; Pepys, MB; Purvis, A; Suzuki, M; Taylor, GW; Tennent, GA; Thompson, D; Wood, SP; Yamamura, K1

Reviews

4 review(s) available for r-1-(6-(r-2-carboxypyrrolidin-1-yl)-6-oxohexanoyl)pyrrolidine-2-carboxylic acid and Amyloidosis

ArticleYear
Drug targets for amyloidosis.
    Biochemical Society transactions, 2010, Volume: 38, Issue:2

    Topics: Amyloidosis; Animals; Carboxylic Acids; Cross-Linking Reagents; Drug Delivery Systems; Humans; Models, Biological; Models, Molecular; Neurodegenerative Diseases; Prealbumin; Protein Binding; Protein Multimerization; Pyrrolidines; Serum Amyloid P-Component

2010
[New trends in the treatment of amyloidosis].
    Medicina clinica, 2012, May-26, Volume: 138, Issue:15

    Topics: Amyloid; Amyloidosis; Carboxylic Acids; Humans; Immunotherapy; Propane; Protein Conformation; Pyrrolidines; Sulfonic Acids

2012
Amyloidosis: a clinico-pathophysiological synopsis.
    Seminars in cell & developmental biology, 2004, Volume: 15, Issue:1

    Topics: Acetylglucosamine; Amyloid; Amyloid beta-Protein Precursor; Amyloidosis; Amyloidosis, Familial; Carboxylic Acids; Flufenamic Acid; Humans; Immunotherapy; Peptides; Prealbumin; Protein Binding; Protein Folding; Protein Precursors; Proteoglycans; Pyrrolidines; Serum Amyloid P-Component

2004
Drug Insight: emerging therapies for amyloidosis.
    Nature clinical practice. Nephrology, 2006, Volume: 2, Issue:5

    Topics: Alzheimer Disease; Amyloidosis; Animals; Anti-Inflammatory Agents, Non-Steroidal; Carboxylic Acids; Diflunisal; Humans; Immunotherapy; Protein Folding; Pyrrolidines

2006

Trials

3 trial(s) available for r-1-(6-(r-2-carboxypyrrolidin-1-yl)-6-oxohexanoyl)pyrrolidine-2-carboxylic acid and Amyloidosis

ArticleYear
Pharmacodynamic evaluation and safety assessment of treatment with antibodies to serum amyloid P component in patients with cardiac amyloidosis: an open-label Phase 2 study and an adjunctive immuno-PET imaging study.
    BMC cardiovascular disorders, 2022, 02-13, Volume: 22, Issue:1

    Topics: Aged; Aged, 80 and over; Amyloidosis; Antibodies, Monoclonal; Carboxylic Acids; Cardiomyopathies; Drug Therapy, Combination; Female; Humans; Magnetic Resonance Imaging; Male; Myocardium; Positron-Emission Tomography; Predictive Value of Tests; Pyrrolidines; Serum Amyloid P-Component; Time Factors; Treatment Outcome; United Kingdom; United States; Ventricular Function, Left; Ventricular Remodeling

2022
An observational, non-interventional study for the follow-up of patients with amyloidosis who received miridesap followed by dezamizumab in a phase 1 study.
    Orphanet journal of rare diseases, 2022, 07-09, Volume: 17, Issue:1

    Topics: Amyloidosis; Carboxylic Acids; Follow-Up Studies; Humans; Plaque, Amyloid; Pyrrolidines; Serum Amyloid P-Component

2022
Therapeutic Clearance of Amyloid by Antibodies to Serum Amyloid P Component.
    The New England journal of medicine, 2015, Sep-17, Volume: 373, Issue:12

    Topics: Adult; Aged; Amyloidosis; Antibodies, Monoclonal; Carboxylic Acids; Dose-Response Relationship, Drug; Humans; Immunoglobulin G; Immunoglobulin Light-chain Amyloidosis; Infusions, Intravenous; Liver; Middle Aged; Pyrrolidines; Radionuclide Imaging; Serum Amyloid P-Component

2015

Other Studies

4 other study(ies) available for r-1-(6-(r-2-carboxypyrrolidin-1-yl)-6-oxohexanoyl)pyrrolidine-2-carboxylic acid and Amyloidosis

ArticleYear
Targeted treatment for amyloidosis.
    The Israel Medical Association journal : IMAJ, 2014, Volume: 16, Issue:5

    Topics: Amyloid; Amyloidosis; Carboxylic Acids; Disease Management; Genetic Therapy; Humans; Molecular Targeted Therapy; Plaque, Amyloid; Prealbumin; Protein Stability; Pyrrolidines; Sequestering Agents; Serum Amyloid A Protein; Serum Amyloid P-Component

2014
Immunoradiometric assay for human serum amyloid P component.
    Journal of immunological methods, 2011, Aug-31, Volume: 371, Issue:1-2

    Topics: Alzheimer Disease; Amyloidosis; Blood Chemical Analysis; Carboxylic Acids; Enzyme-Linked Immunosorbent Assay; Humans; Immunoassay; Immunoradiometric Assay; Protein Stability; Pyrrolidines; Serum Amyloid P-Component

2011
[Novel therapeutic approach to amyloidosis: no implications as yet for patients with Alzheimer's disease].
    Nederlands tijdschrift voor geneeskunde, 2002, Sep-14, Volume: 146, Issue:37

    Topics: Alzheimer Disease; Amyloidosis; Carboxylic Acids; Humans; Protein Folding; Pyrrolidines; Serum Amyloid P-Component

2002
Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis.
    Nature, 2002, May-16, Volume: 417, Issue:6886

    Topics: Amyloidosis; Animals; Calcium; Carboxylic Acids; Cross-Linking Reagents; Crystallography, X-Ray; Dimerization; Humans; Inhibitory Concentration 50; Liver; Mice; Models, Molecular; Protein Binding; Protein Structure, Quaternary; Pyrrolidines; Serum Amyloid P-Component

2002